StockData

Biogen vs Scholar Rock

BIIB and SRRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BIIB and SRRK compare

Biogen is the larger company, worth 6.8 times as much as Scholar Rock ($37.1B against $5.5B).

Biogen scores higher on the StockData Score (4 against 2 for Scholar Rock), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBIIBSRRK
Size and price
Market cap$37.1B$5.5B
Share price$250.79$45.08
Change, 1 year49.7%20.5%
Change, 5 years3.2%67.1%
Beta (5Y)0.140.83
Employees7,500289
StockData Score
Total score4 (better)2
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score22
Dividend score00
Valuation
P/E107×–
P/S3.6×–
P/B–21.6×
EV/EBITDA21.9×–
P/FCF17.9×–
FCF yield5.6% (better)−5.4%
Fair value$160.54–
Margin of safety−56.2%–
Growth
Revenue growth (TTM)2.3%–
Revenue growth, 5Y average−6.0%–
Net income growth (TTM)−78.4%–
EPS growth (TTM)−78.7%–
EPS growth, 5Y average−18.7%–
Profitability
Gross margin74.0%–
Net margin3.4%–
FCF margin20.1%–
Return on equity–−168%
Financial health
Debt / equity–0.77
Interest coverage–−38.0×
Current ratio1.957.02 (better)
Altman Z-score3.076.59 (better)
Piotroski F-score4 (better)1
Dividends and buybacks
Buyback yield–−4.6%
Shareholder yield0.00% (better)−4.6%
Ownership
Held by institutions96.2%114%
Held by insiders0.21%28.9%
Insider net buying, 12 months−$905K (better)−$7.4M
Superinvestors holding1–
Short interest, % of float3.7%27.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.